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Abstracts / Urological Science 26 (2015) S1eS25S12voiding residual urinary amount increased and it improved capacity of
bladder that more than 200ml. The patients are satisﬁed with the outcome
of bladder augmentation and it improved the quality of life. Few times of
urinary tract infection are encountered during follow up in 2 patients. One
patient suffered from recurrent vesical stone without sepsis.
Conclusion: We shared our experience for refractory bladder pain due to
ketamine associated cystitis. The outcome of treatment depends on the
severity of the disease process. Although small number cases, bladder
augmentation may be needed in such patients. It improves bladder ca-
pacity and quality of life of the patients.Podium-7
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Purpose:Aim: Reliable biomarkers are in urgent need for diagnosis, outcome
prediction or treatment effect monitoring for upper tract urothelial carci-
nomas (UTUC). Although up-regulation of cyclooxygenase 2 (COX-2) are
found in stroma and tumor cells in more than half of the UTUC patients
investigated, the genomic contribution ofCOX-2 toUTUC is never studied. The
study was to evaluate the association of six polymorphic genotypes of COX-2
with UTUCwithin a Taiwanese population. Materials andMethods: A total of
218 UTUC patients and 580 healthy controls were genotyped for six COX-2
polymorphisms, A-1195G,G-765C, T+8473C, intron 1, intron5, and intron6, of
their association with UTUC risk. Results: The distribution of genotypes of
COX-2G-765Cand intron5were signiﬁcantly different betweenUTUCpatient
and control groups (p ¼ 0.0001 and 0.0016, respectively), while others were
not (p>0.05). The haplotype analysis showed that compared with GG/TT
haplotype of COX-2 G-765C/intron 5, people carrying GG/AT variants have a
signiﬁcant increased risk of UTUC (odds ratio, OR ¼ 4.83, 95% conﬁdence in-
terval, 95%CI ¼ 1.79-13.06) while people carrying CG/TT variants have a
decreased risk (OR ¼ 0.26, 95%CI ¼ 0.14-0.49). Conclusion: Our results sug-
gested that individual and combinedCOX-2G-765C/intron 5 genotypes play a
role in controlling the COX-2 expression and UTUC development.
Materials and Methods: Sample collection. A total of 218 patients with
UTUC were recruited at China Medical University and Kaohsiung Medical
University medical centers, all of whom were diagnosed by pathologic
examination of specimens obtained by biopsy or surgical resection. The
clinical and histopathologic informationwere collected from patient charts
and pathologic reports. The information was reviewed, and the data were
entered into the database. The tumor stage was assigned according to the
TNM staging system (21), and the pathologic grade was determined ac-
cording to the World Health Organization criteria (22). Five hundreds and
eighty healthy individuals, who had been matched with the patients with
age, admitted to the same hospital for health checkup and who had no
previous diagnosis of urologic neoplastic disease or othermalignancywere
enrolled as controls. All the subjects enrolled were provided an informed
consent and Human Research Committees have approved this study.
Genotyping conditions. The total genomic DNA of each subject was extracted
from the leucocytes of peripheral blood and stored as previously published
(23-25). The polymerase chain reaction (PCR) cycling conditions were: one
cycle at 94

C for 5 min; 35 cycles of 94

C for 30 sec, 55

C for 30 sec, and 72

Ca These Authors contribute equally to this work.for 30 sec, and a ﬁnal extension at 72

C for 10 min. Pairs of PCR primer se-
quences and restriction enzyme for each DNA product of COX-2 genotyping
work are all listed in Table I. The PCR products were cut by proper restriction
enzymes and the reaction was incubated for 2 h at 37

C. Then, 10 ml of each
PCR product was loaded into a 3% agarose gel for electrophoresis.
Statistical analyses. Two hundreds and eighteen cases and ﬁve hundreds and
eighty controls were analyzed in the presented Tables. To ensure that the
controls used were representative of the general population and to exclude
thepossibility of genotypingerror, thedeviation of the genotype frequencies
of COX-2 single nucleotide polymorphism in the controls from those ex-
pected under the Hardy-Weinberg equilibrium was assessed using the
goodness-of-ﬁt test. Pearson's chi-square test or Fisher's exact test (when
the expected number in any cell was less than ﬁve)was used to compare the
distribution of the COX-2 genotypes between cases and controls. Cancer risk
associated with the genotypes was estimated as odds ratio (ORs) and 95%
conﬁdence intervals (CIs) using unconditional logistic regression. All sta-
tistical tests were performed using SPSS for Windows (version 14.0; SPSS
Inc., Chicago, IL, USA) on two-sided probabilities. The correlation between
categorical variables was calculated for statistical signiﬁcance using Pear-
son's chi-square test and the threshold for signiﬁcance was p<0.05.
Results: The frequency distributions of clinical characteristics for the
subjects (218 UTUC patients and 580 healthy controls) are shown in Table
II. Epidemiologically, there was no difference in the frequency distribution
between the gender (p ¼ 0.4256) or age (p ¼ 0.8518) since the population
was well matched (Table II). From the clinical and pathological viewpoints,
tumors distributed in renal pelvic, ureter and multiple sites were 38.5%,
34.9% and 26.6%, respectively. Among the patients, 60.6% were high grade,
and 77.1% were of stages lower than pT3 (Table II).
The frequencies of the genotypes for COX-2 A-1195G, G-765C, T+8473C,
intron 1, intron 5, and intron 6 among the UTUC patients and healthy
controls are summarized and analyzed in Table III. Among the six poly-
morphic genotypes investigated, two of them, G-765C (OR ¼ 0.32, 95%
CI ¼ 0.19-0.55, p ¼ 0.0001) and intron 5 (OR ¼ 3.91, 95%CI ¼ 1.71-8.95,
p¼ 0.0016), were found to be differentially distributed between UTUC case
and control groups (Table III). First, the frequencies of GG and CG geno-
types of COX-2 G-765C were 92.7 and 7.3% among UTUC cases, and 80.2
and 19.8% among healthy controls, respectively. Second, the frequencies of
TT and AT genotypes of COX-2 intron 5 were 93.6 and 6.4% among UTUC
cases, and 98.1 and 1.9% among healthy controls, respectively (Table III). As
for other polymorphic sites of COX-2, there was no difference in the dis-
tribution of genotypes among UTUC cases and controls (Table III). In the
next step, we have performed the allelic frequency analysis, and the fre-
quencies of the alleles for COX-2 A-1195G, G-765C, T+8473C, intron 1,
intron 5, and intron 6 among the UTUC cases and healthy controls are
summarized in Table IV. Consistent to the ﬁndings of Table III, G-765C and
intron 5 of COX-2were found to be associatedwith UTUC risk in Table IV. In
detail, higher frequencies of G allele in G-765C and A allele in intron 5 in
the UTUC case group than the control group, associating to higher risk of
UTUC (Table IV; p ¼ 0.0001 and 0.0017, respectively). Regarding to the
other four COX-2 polymorphic sites, no distribution of their allelic fre-
quencies was found to be signiﬁcantly different between the control and
UTUC case groups (Table IV). Considering the possible interactions be-
tween the two determinant COX-2 genotypes for UTUC susceptibility, the
haplotypic distributions of COX-2 G-765C and intron 5 were further
analyzed (Table V). We have set the most abundant genotypes for both G-
765C and intron 5 genotypes as wild-type for haplotypic combination.
Under this criteria, the “GG” genotype for COX-2G-765C and “TT” for COX-2
intron 5 were selected, resulting in setting GG/TT combinative genotype in
G-765C/intron 5 as the reference haplotype. Compared with the reference
haplotype of COX-2 G-765C/intron 5, the GG/AT group has a signiﬁcant
higher risk of UTUC (OR ¼ 4.83, 95%CI ¼ 1.79-13.06, p ¼ 0.0014) while CG/
TT has a lower risk (OR ¼ 0.26, 95%CI ¼ 0.14-0.49, p ¼ 0.0001) (Table V).
After adjusting for age and gender, the signiﬁcances became more obvious
for the GG/AT and CG/TT groups with their individual ORs altered to 4.86
and 0.32, remained statistically signiﬁcant (Table V). The combination of
CG/AT did not confer signiﬁcantly altered cancer risk compared to the
wild-type haplotype before or after adjusting for age and gender (Table V).
Conclusion: Urothelial carcinoma is the second most common cancer
which usually arises from the urothelium with transitional cell differen-
tiation, including that of the renal pelvis, ureter and bladder. In literature,
a These authors contributed equally to this work.
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genomic variations to bladder cancer (26-30), while few to UTUC (7, 31,
32). Following the rule of molecular central dogma, the single nucleotide
variations on COX-2 among people may determine their differential
expression of COX-2 and personal susceptibility to cancers. The supporting
data comes from that COX-2 is often undetectable in normal tissues,
whereas overexpression of COX-2 has been observed in neoplastic cells of
canine (33) and human RCC (34-36). In our previous report, COX-2 was
found to be up-regulated in both stromal and tumor cells of more than half
of the UTUC patients and the positive expression of COX-2 in stromal cells
may be a biomarker for UTUC-speciﬁc death and recurrence (10). However,
the contribution of COX-2 genotypes to UTUC has never been studied. In
this study, the genotypes of COX-2 of 218 UTUC patients together with 580
controls (Table III) were examined. Statistically, the distributions of COX-2
genotypes for G-765C and intron 5 were differentially distributed among
the UTUC and healthy control groups (Table III). In addition, the allelic
frequencies of the two polymorphisms were also differentially distributed
between the two groups (Table IV). The results showed that the G allele of
G-765C and A allele of intron 5 were associated with higher risk for UTUC
and the haplotype analysis suggested that individuals with GG/AT and CG/
TT haplotypes at G-765C/intron 5 were at altered risk of UTUC before and
after adjusting of gender and age (Table V). UTUC is not a common cancer
in Taiwan and the world, which may be one of the limitation for genomic
study of UTUC. Compared with previous ﬁnding, we have enlarged the
sample size from 56 cases and 436 controls in 2011 (37) to 218 cases and
580 controls (Table II). The strengthened sample size and the same trend of
signiﬁcant genotype distribution after age and gender adjustments high-
lighted the value, accuracy and reliability of the overall ﬁndings (Table V).
This is the ﬁrst UTUC genomic study showing COX-2 G-765C and intron 5
genotypes were associated with UTUC risk. The G allele of Cox-2 G-765C and
A allele of COX-2 intron 5 were genomic risk factors and may serve as early
screening and prediction biomarkers for UTUC in Taiwan and all over the
world.
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Purpose: Urothelial carcinoma (UC) is common in urinary bladder (UB)
and upper urinary tract (UT). It represents a heterogeneous disease with
high morbidity and mortality. Tumor invasion and progression are a
multifactorial process promoted by microenvironmental changes that
include overexpression of matrix metalloproteinases (MMPs). Through
data mining from a published transcirptomic database of UBUCs
(GSE32894), MMP11 was identiﬁed as the most signiﬁcant gene showing
stepwise upregulation among those associated with the regulation of
metalloendopeptidase activity. We therefore analyze MMP11 protein
expression and its association with clinicopathological factors and sur-
vivals in our well-characterized cohort of UC.
Materials andMethods: Immunohistochemistry evaluated by usingH-score
was used to determine MMP11 protein expression in 295 UBUCs and 340
UTUCs, respectively. The medical records of these patients were reviewed
retrospectively. The MMP11 expression status was further correlated with
clinicopathological features as well as disease-speciﬁc survival (DSS) and
metastasis-free survival (MeFS). Univariate and multivariate statistical ana-
lyses were performed to evaluate the prognostic predictors.Results: MMP11 protein overexpression was signiﬁcantly associated with
advanced pT status (UTUC, p<0.001; UBUC, p<0.001), nodal metastasis
(UTUC, p<0.001; UBUC, p ¼ 0.012), vascular invasion (UTUC, p<0.001;
UBUC, p<0.001) and perineural invasion (UTUC, p ¼ 0.002; UBUC,
p¼ 0.006) in both groups of UC. MMP11 overexpression not only predicted
worse DSS (UTUC, p<0.0001; UBUC, p<0.0001) and MeFS (UTUC,
p<0.0001; UBUC, p<0.0001) at univariate analysis, but implicated inferior
DSS (UTUC, p¼ 0.005; UBUC, p¼ 0.010) andMeFS (UTUC, p¼ 0.018; UBUC,
p ¼ 0.026) in multivariate analysis.
Conclusion: MMP11 overexpression is associated with more aggressive
tumor phenotype and poor prognosis for both patients with UTUC and
UBUC, suggesting it may serve as a potential prognostic and a novel
therapeutic target of UC.
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Purpose: Galactin-1 plays an important role in oncogenic processes. In
several literatures, it has been studied that Galactin-1 is highly related to
some cancers, including hepatocellular carcinoma and breast cancer. In our
present study, we try to clarify the relationship between Galactin-1 over-
expression and prognosis of urinary bladder urothelial carcinoma (UC).
Materials and Methods: We reviewed 185 patients who had bladder UC
and received transurethral resection of bladder tumor. The spacemen was
re-examed by pathologist and further survey about cytoplasmic galactin-1
immunoexpression was performed. Then we correlate the laboratory data
to clinical disease prognosis under statistical analyses.
Results: Positive galectin-1 immunoexpression in tumor signiﬁcantly links
with increment of pT status (p ¼ 0.0295) as well as histological grade
(p ¼ 0.037), the presence of vascular invasion (p ¼ 0.0287), nodal status
(p ¼ 0.0012), high mitotic activity (p ¼ 0.0015) and tumor necrosis
(p ¼ 0.0246). Galectin-1 over-expression in tumor cell predicts the dis-
ease-speciﬁc survival in univariate (P ¼ 0.0002) and multivariate analysis
(P ¼ 0.03, HR ¼ 2.438). Besides, gene of galactine-1 (as LGALS1 gene)
ampliﬁcation is also linked to disease-speciﬁc survival rate (P ¼ 0.0006).
Conclusion: Galectin-1 over-expression is an adverse factor to predict the
prognosis of urinary bladder UC. It may help us about clinical decision
making and outcome prediction. Further relationship between urinary
bladder UC and galactin-1 can be studied on the base of this present study.
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Purpose: Cancer cells adapt to the stress resulting from accelerated cells
growth, lack of nutrients or challenges of anti-cancer drugs by activation of
the autophagy pathway. We demonstrated that human bladder cancer cells
exhibit high level of basal autophagy in our previous studies. We therefore
hypothesize that autophagy inhibitors such as chloroquine (CQ) and
hydroxychloroquine (HCQ) that inhibits autophagosome functionwill result
in cancer cell death by induction of apoptosis in human bladder cancer cells.
Materials and Methods: Human Immortalized uroepithelial cell, SV-Huc-
1; human bladder cancer cells including: transitional cell carcinoma (TCC)
grade I, RT-4; TCC grade II, 5637; TCC grade III, T24; human prostate cancer
